SGLT-2抑制剂在心血管疾病中的应用及研究进展  

Application of SGLT-2 inhibitor in cardiovascular diseases and its research progress

作　　者：胡雨欣 项莹[1] HU Yu-xin;XIANG Ying(Department of Endocrinology,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150001,China)

机构地区：[1]哈尔滨医科大学附属第二医院内分泌科,黑龙江哈尔滨150001

出　　处：《心血管康复医学杂志》2020年第4期495-498,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂是一种新型的口服降糖药物,其除了具有降糖作用外,还具有减轻体重,降低血压、尿酸和甘油三酯水平,降低心血管死亡率和心力衰竭住院率等作用.同时,一些研究发现SGLT-2抑制剂尚存在引起低血糖、增加感染风险,导致严重酮症酸中毒等潜在副作用.本文将对SGLT-2抑制剂的降糖机制、心血管效应、潜在副作用几个方面进行总结,以期为该类药物的研究发展和临床治疗提供借鉴意义.Sodium glucose cotransporter 2(SGLT-2)inhibitor is a novel oral hypoglycemic drug.Besides hypoglyce-mic effect,it can also reduce weight,levels of blood pressure,uric acid and triglyceride,cardiovascular mortality and hospitalization rate of heart failure etc.However,some researches found that SGLT-2 inhibitor still possesses potential side effects,such as hypoglycemia,increasing infection risk and leading to severe ketoacidosis etc.The present article summarizes hypoglycemic mechanism,cardiovascular effect and potential side effects of SGLT-2 in-hibitor,aiming at providing reference for research development and clinical treatment of this drug.

关 键 词：心血管疾病 糖尿病 2型 钠-葡萄糖转运蛋白质类 

分 类 号：R54[医药卫生—心血管疾病]